Abstract 808P
Background
Human papillomavirus (HPV) is the cause of the majority of cervical cancer cases and has been suggested to be released as cell-free DNA (ctHPV DNA) into the circulation. We here analyse if ctHPV DNA could be detected in plasma from patients with locally advanced cervical cancer (LACC) and if ctHPV DNA could be used as a prognostic biomarker and/or to detect relapses earlier than by traditional methods.
Methods
74 patients with LACC were included, 66/74 had biopsies positive for one of 13 high-risk HPV-types using a bead-based assay. Droplet digital PCR (ddPCR) assays were developed for the HPV-types found. 418 longitudinal plasma samples from these 66 patients were then analysed using ddPCR assays for the corresponding HPV-type found in the biopsies. Results were correlated to tumor- and clinical characteristics.
Results
92.4% of pre-treatment plasmas were positive for ctHPV DNA. ctHPV DNA levels were correlated to tumor stage. Persistent ctHPV DNA in end-of-treatment or early follow-up (1-4 months after finished treatment) plasma were correlated with worse progression-free survival (log rank test, p < 0.001) compared to if ctHPV DNA was not found. The positive predictive value (PPV) of ctHPV-status at early follow-up for predicting disease progression was 87.5% and the negative predictive value (NPV) was 89.3%. ctHPV DNA was found in plasma before relapse was diagnosed on radiology (median 315 days, mean 280 days) in all patients (n=10) who experienced relapsed after complete clinical response to treatment.
Conclusions
ctHPV DNA in follow-up plasma is a promising prognostic biomarker in patients with locally advanced cervical cancer, useful for analysis of response to therapy and for early detection of relapses. Drs. E. Tham and K. Hellman have equally contributed to the study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Karolinska Institutet, Magnus Bergvalls Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
758P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Mathilde Saint-Ghislain
Session: Poster session 11
759P - Nimotuzumab combined with concurrent chemo-radiotherapy in patients with locally advanced cervical squamous cell carcinoma: A randomized, controlled, open-label, multicenter study
Presenter: Junjie Wang
Session: Poster session 11
760P - Efficacy and safety of nimotuzumab plus radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma
Presenter: Ang Qu
Session: Poster session 11
761P - A phase II trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer (GEICO 70-E): analysis according to molecular classification
Presenter: Josep M. Piulats
Session: Poster session 11
764P - Tislelizumab (Anti-PD-1) combined with definitive chemoradiotherapy in recurrent and/or metastatic cervical cancer (PILOT-2020-511): A single-arm, phase II trial
Presenter: JUN ZHU
Session: Poster session 11
765P - SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
Presenter: Xiaohua Wu
Session: Poster session 11
766P - A comparative study of sequential and interdigitated brachytherapy with chemoradiation in patients of locally advanced carcinoma cervix
Presenter: Shreya Singh
Session: Poster session 11
767P - Phase I/II study of toripalimab with cisplatin-based concurrent IMRT for local advanced cervical cancer
Presenter: Ping Jiang
Session: Poster session 11